A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Hookipa Pharma Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 302,246 shares of HOOK stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
302,246
Previous 218,446 38.36%
Holding current value
$1.1 Million
Previous $156,000 14.1%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.59 - $1.04 $49,442 - $87,152
83,800 Added 38.36%
302,246 $178,000
Q1 2024

May 13, 2024

BUY
$0.61 - $0.83 $18,178 - $24,734
29,800 Added 15.8%
218,446 $156,000
Q4 2023

Feb 13, 2024

SELL
$0.42 - $0.86 $154,135 - $315,611
-366,990 Reduced 66.05%
188,646 $153,000
Q3 2023

Nov 14, 2023

SELL
$0.58 - $0.91 $205,436 - $322,322
-354,200 Reduced 38.93%
555,636 $342,000
Q2 2023

Aug 11, 2023

BUY
$0.71 - $1.97 $637,605 - $1.77 Million
898,036 Added 7610.47%
909,836 $801,000
Q1 2023

May 12, 2023

SELL
$0.72 - $1.03 $18,072 - $25,853
-25,100 Reduced 68.02%
11,800 $9,000
Q4 2022

Feb 13, 2023

SELL
$0.73 - $14.6 $76,869 - $1.54 Million
-105,300 Reduced 74.05%
36,900 $30,000
Q3 2022

Nov 14, 2022

BUY
$1.27 - $15.0 $60,325 - $712,500
47,500 Added 50.16%
142,200 $191,000
Q2 2022

Aug 12, 2022

BUY
$1.33 - $2.31 $125,951 - $218,757
94,700 New
94,700 $154,000
Q1 2022

May 13, 2022

SELL
$1.26 - $2.52 $494,928 - $989,856
-392,800 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$2.33 - $5.94 $915,224 - $2.33 Million
392,800 New
392,800 $915,000
Q3 2020

Nov 13, 2020

SELL
$8.59 - $11.89 $214,028 - $296,251
-24,916 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$7.23 - $12.1 $180,142 - $301,483
24,916 New
24,916 $290,000

Others Institutions Holding HOOK

About HOOKIPA Pharma Inc.


  • Ticker HOOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,654,500
  • Market Cap $188M
  • Description
  • HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...
More about HOOK
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.